OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
January 15, 2021
This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
The first four investments of the new program will support clinical-stage biotechnology companies while new investments will include companies focused on oncology, rare disease, and inflammation and immunology.
The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.
January 06, 2021
Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.
January 05, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
January 03, 2021
Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.
Essential bio/pharma employees show hard work and dedication can pay off for patients.
Demand for specific advanced laboratory skills drives creates a positive employment market.
January 02, 2021
Shutting down the COVID-19 pandemic requires a global, selfless effort.